Accéder au contenu
Merck
  • Urinary messenger RNA of the receptor activator of NF-kappaB could be used to differentiate between minimal change disease and membranous nephropathy.

Urinary messenger RNA of the receptor activator of NF-kappaB could be used to differentiate between minimal change disease and membranous nephropathy.

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2014-08-30)
Shuangxin Liu, Ping Mei, Wei Shi, Bin Zhang, Sijia Li, Xinling Liang, Zhiming Ye, Lixia Xu, Jianchao Ma, Zhilian Li, Li Zhang, Wenjian Wang, Liping Wang, Rizhao Li, Zhonglin Feng, Wei Dong, Yiming Tao
RÉSUMÉ

Podocyte damage and loss together have an important role in the pathogenesis and progression of glomerulonephritis. Glomerulonephritis patients and healthy controls were enrolled in this study. Biochemical, clinical and experimental procedures included measurement of total urinary protein, renal biopsy and gene expression analysis of the receptor activator of NF-kappaB (RANK). The urinary mRNA levels of RANK were significantly higher in the glomerulonephritis group compared to the controls. The urinary RANK level of glomerular subtypes was correlated significantly with proteinuria. The calculated area of RANK mRNA levels under the curve was 0.61 for minimal change disease (MCD), 0.97 for membranous nephropathy (MN), 0.65 for IgA nephropathy (IgAN), 0.70 for lupus nephritis (LN) and 0.70 for focal segmental glomerulosclerosis (FSGS). The urinary mRNA of RANK might be used to differentiate histologic subtypes of glomerulonephritis, particularly between MCD and MN.